Association between asymptomatic intracranial arterial stenosis and insulin resistance or diabetes mellitus: a cross-sectional study in rural Shandong, China

Qiao Wang,1 Yuanyuan Zhao,1,2 Xiang Wang,1,2 Xiaokang Ji,3 Shaowei Sang,4 Sai Shao,5 Xiaotong Ma,1,2 Guanbing Wang,5 Ming Lv,4 Fuzhong Xue,3 Yifeng Du,1,2 Qinjian Sun 1,2

ABSTRACT

Introduction Recent studies have shown that insulin resistance (IR) is correlated to atherosclerosis development. However, few studies have investigated the association between IR and asymptomatic intracranial arterial stenosis (aICAS).

Research design and methods This cross-sectional study enrolled 2007 rural residents in China who were aged ≥40 years without a clinical history of stroke and transient ischaemic attack. We used transcranial Doppler ultrasonography in combination with magnetic resonance angiography to diagnose aICAS (stenosis ≥50%). IR was defined as a homeostasis model assessment of insulin resistance ≥3.0 based on the 75th percentile for all the participants. Multivariate logistic regression models were employed to assess the relationship of diabetic parameters with aICAS in all participants, as well as with aICAS in non-diabetic participants, and further stratified by sex.

Results After adjusting for age, gender, smoking habit, drinking habit, low-density lipoprotein cholesterol, raised blood pressure, triglycerides, high-density lipoprotein cholesterol, and waist circumference, diabetes mellitus (DM) (OR=2.09, 95% CI 1.31 to 3.32), fasting plasma glucose (FPG) (OR=1.34, 95% CI 1.14 to 1.57), and IR (OR=1.75, 95% CI 1.11 to 2.75) were associated with aICAS in the total study population; however, these relationships remained significant only in men after the analyses were stratified by sex (DM: OR=3.40, 95% CI 1.62 to 7.13; FPG: OR=1.64, 95% CI 1.26 to 2.13; IR: OR=3.04, 95% CI 1.44 to 6.42). When further excluding the diabetic participants from the total study population, positive associations between IR and aICAS were similarly observed only in men (OR=4.65, 95% CI 1.69 to 12.82).

Conclusions IR might predict the prevalence of aICAS independently of major cardiovascular risk factors and metabolic syndrome components among men living in rural China.

INTRODUCTION

Intracranial arterial stenosis (ICAS) is a leading cause of ischemic stroke worldwide and remains a significant target for stroke prevention, particularly among Asian populations.1 The identification of the modifiable risk factors associated with asymptomatic ICAS (aICAS) may facilitate the primary prevention of clinical stroke.2 However, one large-scale study reported that cardiovascular risk factors (CRFs), such as hypertension, diabetes mellitus (DM), dyslipidemia and obesity, could only explain <40% of the carotid intima-media thickness variance.3 Therefore, there is increasing interest in the investigation of new CRFs.

Type 2 DM is characterized by insulin resistance (IR), with elevated fasting plasma...
cardiovascular and metabolic risk

The association of aICAS with FPG was well established in previous studies. However, the association between IR and aICAS was unknown. As we all know, IR is associated with proinflammatory activity, influencing the endothelial function and macrophage recruitment. A Spanish study concluded that IR was an independent predictor of moderate to severe ICAS after adjustment of the rest of MetS components, while other studies have shown that IR may increase the atherosclerosis-related risks directly by mediating proinflammatory activity, influencing the endothelial function and macrophage recruitment. 

Due to the biological differences between men and women, including sex hormones levels, they share different risk factor profiles of intracranial atherosclerosis. Previous studies have shown that higher IR measured with homeostatic model assessment of insulin resistance (HOMA-IR) increased the risk of coronary calcification, independently of the presence of MetS components in Japanese men, and lower insulin sensitivity, measured using the euglycemic hyperinsulimemic clamp test, was associated with higher carotid intima-media thickness after the adjustment of the established risk factors in apparently healthy European men. Both of the two studies were analyzed among male population; therefore, the sex-based differences on the association of aICAS and IR in a general population remain unclear.

IR can be diagnosed using the euglycemic hyperinsulimemic clamp test that is considered the gold standard method for accurate assessment of insulin sensitivity. However, the use of this method is not feasible in large-scale or epidemiological studies owing to the expensive and time-consuming procedures involved. HOMA-IR derived from the mathematical modeling of FPG and insulin concentrations is a simple and inexpensive alternative for the evaluation of insulin sensitivity and has been widely accepted in large-scale studies because of its cost-effectiveness, convenience, and good correlation with the results of the gold standard method.

Thus, the present study aimed to evaluate whether IR or DM is associated with aICAS prevalence independently of MetS components and conventional CRFs and to explore if the sex-based differences on the association between aICAS and IR or DM exist or not in a rural Chinese population.

METHODS
Study design and study population
Participants in this study were enrolled in the Konggun Town Study, which has been described in detail previously. The Konggun Town Study is an ongoing population-based study that aimed to investigate the prevalence of aICAS and major CRFs or biomarkers related to the development and prognosis of aICAS. Briefly, 2311 rural residents have been enrolled who are aged ≥40 years without a clinical history of stroke or transient ischaemic attack and living in Konggun Town, Shandong Province, China. From October 2017 to October 2018, information on demographics, socioeconomic, personal and family medical history, and lifestyle factors was collected through face-to-face interviews, physical examination and blood tests, and all the participants underwent transcranial Doppler (TCD) ultrasonography in phase I. Finally, 204 participants who were positive for aICAS on TCD ultrasonography were invited to undergo brain magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) examinations in phase II.

Participants were excluded from this study if they had missing information about demographics, anthropometric measurements, TCD ultrasonography and blood test results, or with outlier of any continuous variables. Participants who were contraindicated for brain MRI and MRA, such as those with pacemakers and metal denture implantations were also excluded.

All the participants provided written informed consent for study participation. This study was conducted as per the principles for medical research involving human participants expressed in the Helsinki Declaration.

Data collection and assessment
Data on demographic characteristics, CRFs, anthropometric measurements, and blood biochemical markers were collected, as described previously. The fasting insulin level was measured using the electrochemiluminescence immunoassay (Roche Diagnostics, Mannheim, Germany). In this study, we defined hypertension as blood pressure level ≥140/90 mm Hg, use of antihypertensive drugs, or a previous diagnosis of hypertension. DM was defined as a FPG level ≥7.00 mmol/L, use of antihypoglycemic drugs, insulin injection, or self-reported history of DM. Smoking was defined as smoking at least one cigarette per day for >1 year; current and previous smokers with a history of quitting for <6 months were included. Drinking was defined as alcohol consumption at least once a week for at least 6 months; current and previous drinkers with a history of quitting for <6 months were included.

Assessment of aICAS
The aICAS evaluation protocol has been described in detail previously. In brief, aICAS was initially screened using TCD examination and then diagnosed using MRA. At phase I, two experienced physicians with expertise in sonography performed TCD examination for all participants. The bilateral middle cerebral artery, anterior cerebral artery, posterior cerebral artery, basilar artery were examined through a temporal window, occipital window and eye window, respectively. The diagnosis of ≥50% intracranial stenosis of various arteries followed the criteria described in the Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis trial.
At phase II, participants who were screened positive by TCD underwent structural brain MRI and MRA scans. The severity of stenotic lesion in the examined arteries was classified into five grades as normal, mild (signal reduction <50%), moderate (signal reduction ≥50% and <70%), severe (signal reduction ≥70%) or occlusion, which were completed by a neurologist who specialized in stroke treatment (QS) and a clinical neuroradiologist (GW) together by consensus, according to the criteria in the Warfarin-Aspirin Symptomatic Intracranial Disease Study. All TCD and MRA findings were made blinded to clinical information. A previous study showed that aICAS with stenosis degree >50% could increase the risk of stroke. In addition, signal reduction ≥50% is a more explicit and severe outcome of atherosclerosis; it is more reliable to take signal reduction ≥50% as the definition of aICAS, adding credibility to our findings. Therefore, in this study, aICAS was defined as having at least one lesion (signal reduction ≥50%) in any of the examined arteries.

### Diagnosis of IR and MetS

Insulin sensitivity was measured using HOMA-IR, calculated with the following formula: 
\[
\text{HOMA-IR} = \frac{\text{FPG} (\text{mmol/L}) \times \text{fasting insulin (mU/L)}}{22.5}
\]
IR was defined as a HOMA-IR value ≥3.0 based on the 75th percentile for all the study participants.

As per the 2009 Joint Interim Statement, MetS was diagnosed if at least three of the following conditions were present: waist circumference (≥90 cm for men and ≥80 cm for women), high triglyceride level (≥1.7 mmol/L) or medication, decreased high-density lipoprotein cholesterol (HDL-C) level (<1.0 mmol/L for men and <1.3 mmol/L for women) or medication, increased blood pressure (systolic blood pressure (SBP) ≥130 mm Hg and/or diastolic blood pressure (DBP) ≥85 mm Hg) or medication, and elevated FPG level (≥5.6 mmol/L) or medication.

### Statistical analysis

All the analyses were performed with the Statistical Package for the Social Sciences software V.22.0 for Windows. The characteristics of the study participants are presented as mean and SD values for continuous variables with a normal distribution and as median and IQRs for continuous variables with a non-normal distribution. Categorical variables are presented as frequencies and percentages. Variables were compared as per sex or the presence of aICAS using t-test, Mann-Whitney U test, or \( \chi^2 \) test, as applicable.

We used multivariate logistic regression models to analyze the association between diabetic parameters (DM, FPG level, HOMA-IR, and IR) and aICAS in the total study population to obtain the adjusted ORs and 95% CIs, and considering the multicollinearity between DM and IR, we also investigated the association between diabetic parameters and aICAS in the non-diabetic participants in order to reduce the impact of the increased glucose concentration on the association between IR and aICAS. We further designed post hoc models stratified by sex. We reported the results from two models: model 1 was adjusted for age, sex, smoking habit, alcohol consumption, and low-density lipoprotein cholesterol (LDL-C); model 2 was adjusted for variables in model 1 plus additional MetS components (raised blood pressure, triglycerides, HDL-C, and waist circumference). Continuous variables that had a non-normal distribution were analyzed after logarithmic conversion. ORs were for 1-SD increase in continuous parameters. A p value <0.05 was considered to indicate statistical significance.
Cardiovascular and metabolic risk

RESULTS

Study participants

As shown in figure 1, we excluded 269 participants in phase I, who had missing information about TCD ultrasonography (n=143), fasting insulin level (n=18), and other blood test results (n=106); or with outlier of fasting insulin and glucose concentration (n=2). In phase II, we excluded 35 participants who were contraindicated for brain MRI and MRA, such as those with pacemakers or metal denture implantations. Therefore, of the total 2311 participants who were eligible for study inclusion, 2007 (86.8%) were enrolled.

Participants characteristics

Table 1 presents participants characteristics, stratified as per sex. The prevalence of aICAS was 4.9% (n=99) in the total population, 4.1% (n=39) in men, and 5.7% (n=60) in women. There were sex-based differences in the HOMA-IR value and the prevalence of most CRFs and metabolic risk factors, except SBP, HDL-C level, and hypertension.

Participants characteristics according to the presence of aICAS are shown in table 2. As compared with those without aICAS, participants with aICAS were older, had lower HDL-C levels, and had higher waist circumference, SBP, DBP, triglyceride level and LDL-C level. Moreover, hypertension, DM, MetS, IR, and use of medications for hypertension and DM were more commonly observed in those with aICAS. In terms of lifestyle habits, the participants with aICAS were less likely to be current smokers or alcohol consumer than those without aICAS.

Association between diabetic parameters and aICAS in the total study population

After adjusting age, gender, smoking habit, drinking habit, and LDL-C (model 1), all the diabetic parameters were associated with aICAS in the total population (table 3). After further adjusting the MetS components, including raised blood pressure, triglycerides, HDL-C,
Cardiovascular and metabolic risk

waist circumference (model 2), DM (OR=2.09, 95% CI 1.31 to 3.32), FPG level (OR=1.34, 95% CI 1.14 to 1.57), and IR (OR=1.75, 95% CI 1.11 to 2.75) remained independently associated with aICAS (table 3).

The sex-specific analyses showed that all the diabetic parameters were significantly correlated with aICAS in both male and female participants in model 1. Male participants had higher ORs than female participants. However, after further adjusting the MetS components (in model 2), DM (OR=3.40, 95% CI 1.62 to 7.13), FPG level (OR=1.64, 95% CI 1.26 to 2.13), and IR (OR=3.04, 95% CI 1.44 to 6.42) remained associated with aICAS only in the male participants (table 3).

Association between diabetic parameters and aICAS in the non-diabetic participants

The logistic regression analyses in the non-diabetic participants shows that both FPG (OR=1.91, 95% CI 1.09 to 3.35) and IR (OR=1.79, 95% CI 1.03 to 3.14) were associated with a higher risk of aICAS in model 1. After further adjusting the MetS components (in model 2), these relationships were not statistically significant (table 4).

In the male participants, FPG (OR=2.66, 95% CI 1.01 to 7.01) and IR (OR=4.29, 95% CI 1.17 to 10.84) were associated with having aICAS in model 1; however, only IR (OR=4.65, 95% CI 1.69 to 12.82) was related to a higher probability of having aICAS in model 2. No significant association was found between these diabetic parameters and aICAS in the female participants (table 4).

DISCUSSION

In this population-based study, an independent association was found between IR or DM and aICAS after the adjustment of major CRFs and MetS components in apparently healthy Chinese men. The association between IR and aICAS remained significant in further analysis among non-diabetic male participants, suggesting that IR may have additive value for predicting aICAS prevalence via mechanisms other than glucose homeostasis.

In the present study, DM and FPG were the independent predictor of the presence of aICAS among the total participants, which is consistent with previous studies. The highlight of this study is that IR was also associated with aICAS, independently of the presence of major CRFs and MetS components in Chinese men, even in non-diabetic male participants. To our knowledge, the Barcelona-Asymptomatic Intracranial Atherosclerosis

Table 2  Demographic and clinical characteristics of study participants by aICAS

| Characteristics                      | aICAS (n=99)          | Non-aICAS (n=1908) | P value* |
|--------------------------------------|-----------------------|--------------------|----------|
| Age (years)                          | 63 (54, 71)           | 55 (49, 65)        | <0.001   |
| Male (n, %)                          | 39 (39.4)             | 918 (48.1)         | 0.090    |
| Waist circumference (cm)             | 94.4 (11.4)           | 91.3 (9.3)         | <0.001   |
| Hypertension (n, %)                  | 83 (83.8)             | 1067 (55.9)        | <0.001   |
| SBP (mm Hg)                          | 159 (149, 178)        | 141 (128, 158)     | <0.001   |
| DBP (mm Hg)                          | 91 (82, 99)           | 87 (79, 96)        | 0.017    |
| Smoking habit (n, %)                 | 8 (8.1)               | 439 (23.0)         | 0.001    |
| Drinking habit (n, %)                | 23 (23.2)             | 634 (33.2)         | 0.039    |
| Total cholesterol (mmol/L)           | 5.31 (4.90, 6.27)     | 5.29 (4.66, 5.96)  | 0.115    |
| Triglyceride (mmol/L)                | 1.42 (1.03, 2.08)     | 1.09 (0.80, 1.60)  | <0.001   |
| HDL-C (mmol/L)                       | 1.47 (1.25, 1.62)     | 1.59 (1.36, 1.88)  | <0.001   |
| LDL-C (mmol/L)                       | 3.13 (2.75, 3.75)     | 2.93 (2.51, 3.39)  | <0.001   |
| Use of cholesterol-lowering medications (n, %) | 0 (0.0)           | 21 (2.8)           | 0.233    |
| Use of antihypertensive medication (n, %) | 38 (45.8)            | 287 (26.9)         | <0.001   |
| FPG (mmol/L)                         | 6.37 (5.54, 7.53)     | 5.62 (5.23, 6.15)  | <0.001   |
| DM (n, %)                            | 35 (35.4)             | 272 (14.3)         | <0.001   |
| Use of glucose-lowering medications (n, %) | 22 (62.9)            | 117 (43.0)         | 0.026    |
| MetS (n, %)                          | 76 (76.8)             | 874 (45.8)         | <0.001   |
| HOMA-IR                              | 2.72 (1.72, 3.70)     | 1.95 (1.26, 2.92)  | <0.001   |
| Fasting insulin (mUI/L)              | 9.43 (5.98, 12.72)    | 7.67 (5.11, 10.91) | 0.003    |
| IR (n, %)                            | 44 (44.4)             | 448 (23.5)         | <0.001   |

Data were shown as numbers (%), mean (SD), and mean (first, third quartiles).
*Comparison according to presence of aICAS using t-test, Mann-Whitney U test and χ² test appropriately. aICAS, asymptomatic intracranial arterial stenosis; DBP, diastolic blood pressure; DM, diabetes mellitus; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; IR, insulin resistance (HOMA-IR ≥3.0); LDL-C, low-density lipoprotein cholesterol; MetS, metabolic syndrome; SBP, systolic blood pressure.
Cardiovascular and metabolic risk

Table 3  Multivariate-adjusted ORs and 95% CIs between asymptomatic intracranial arterial stenosis and diabetic parameters of the total participants and as per sex

| Variables | In all participants (n=2007) | In male participants (n=957) | In female participants (n=1050) |
|-----------|-----------------------------|-----------------------------|-------------------------------|
|           | OR (95% CI)                  | OR (95% CI)                  | OR (95% CI)                   |
| DM*       |                             |                             |                               |
| Model 1   | 2.52 (1.61 to 3.92) <0.001  | 4.11 (2.04 to 8.28) <0.001  | 1.88 (1.05 to 3.36) 0.034     |
| Model 2   | 2.09 (1.31 to 3.32) 0.002   | 3.40 (1.62 to 7.13) 0.001   | 1.53 (0.83 to 2.79) 0.170     |
| FPG†, mmol/L |                        |                             |                               |
| Model 1   | 1.41 (1.21 to 1.64) <0.001  | 1.75 (1.37 to 2.24) <0.001  | 1.24 (1.02 to 1.52) 0.034     |
| Model 2   | 1.34 (1.14 to 1.57) <0.001  | 1.64 (1.26 to 2.13) <0.001  | 1.18 (0.96 to 1.47) 0.124     |
| HOMA-IR†  |                             |                             |                               |
| Model 1   | 1.50 (1.20 to 1.86) <0.001  | 1.61 (1.16 to 2.22) 0.004   | 1.41 (1.04 to 1.90) 0.026     |
| Model 2   | 1.24 (0.97 to 1.59) 0.083   | 1.39 (0.96 to 2.02) 0.084   | 1.12 (0.81 to 1.55) 0.484     |
| IR*       |                             |                             |                               |
| Model 1   | 2.32 (1.52 to 3.54) <0.001  | 3.69 (1.85 to 7.33) <0.001  | 1.76 (1.03 to 2.99) 0.038     |
| Model 2   | 1.75 (1.11 to 2.75) 0.015   | 3.04 (1.44 to 6.42) 0.004   | 1.25 (0.71 to 2.20) 0.441     |
the liver and impaired glucose uptake in the skeletal muscles. The long-term hyperglycemia induced by IR can cause cell damage by triggering oxidative stress and inflammatory response. Moreover, impaired hormone function results in limited degradation of apolipoprotein B induced by impaired PI3K activation and increased synthesis of very low-density lipoprotein, leading to the formation of atherosclerotic plaque.

The independent association between IR and aICAS may be partially explained by its vascular effect. Increasing evidence has shown that in addition to causing metabolic changes, insulin signaling defects under IR also play an important role in the development of atherosclerotic lesions. Under physiological conditions, insulin exerts a protective effect by activating endothelial nitric oxide synthase via the PI3K/Akt pathway. Furthermore, it exerts a detrimental effect because it induces vascular smooth muscle cell proliferation and vasoconstriction via the mitogen-activated protein kinase (MAPK) pathway. Under IR, the PI3K pathway is impaired, while the MAPK pathway remains intact. Thus, the detrimental effects of insulin are more than its protective effects on the vascular beds, leading to the formation of atherosclerosis. Based on the above data, we speculated that physicians may underestimate the possibility of having aICAS when the HOMA-IR value or insulin sensitivity of patients is not available. For the primary prevention of stroke, we need to grade the effects of IR and its related metabolic changes on aICAS in the future.

As we all know, significant differences exist between men and women in sex hormones. A previous have reported the sexual difference on the conventional risk factor profiles of intracranial atherosclerotic disease. However, few studies have focused on the sex-based differences in the new risk factors. In this study, IR was independently associated with aICAS only in male participants. Similarly, sex-based differences were found in some studies on other vessel territories, such as carotid and coronary arteries. The mechanism underlying this difference remains unknown. Some studies have indicated that women have higher endogenous antioxidant capacity than men, which may partially explain the female advantage in eliminating increased IR-related risks. Moreover, in this study, the higher prevalence of unhealthy lifestyle habits and poor management of CRFs in men may partly contribute to this sex-based difference.

In this study, we found only 1.2% of women with smoking habits in rural China, which was not exactly similar to that of two other Chinese studies (2.0% and 2.6%). and 4% of women drink alcohol, which was slightly higher than that in another Chinese study (2%). The reasons for the different prevalence rates across studies are not entirely clear, but differences in demographic features of the study populations (eg, region and age) and methodological issues (eg, definition of smoking habits) may partly contribute to the difference.

To our knowledge, this is the first study to investigate the association between IR and aICAS in rural Chinese population. However, this study has certain limitations that should be considered. First, the cause and effect cannot be explained in this cross-sectional study. The participants with IR in this study should be assessed in longitudinal studies in the future. Second, insulin sensitivity was measured using HOMA-IR rather than the gold standard euglycemic hyperinsulinemic clamp technique. Third, TCD as a tool for screening aICAS might have missed some cases and underestimated the prevalence of aICAS, which may have an impact on the association between IR and aICAS. Fourth, the cut-off value of HOMA-IR (75th percentile) for IR diagnosis in this study cannot be used in other studies because the 75th percentile of HOMA-IR may vary with different populations or different insulin assays. Finally, this study is a single-center study, and generation to the other population should be done with caution, and further large-scale multi-center studies are needed to verify this association and sex-based difference.

CONCLUSIONS

In this study, IR (HOMA-IR ≥3.0) or DM might be associated with the aICAS prevalence, independently of major CRFs and MetS components in Chinese men living in rural communities. Moreover, the association between IR and aICAS remained significant after excluding the diabetic participants, suggesting that IR may be associated with aICAS via mechanisms other than glucose homeostasis. This sex-based difference may facilitate improvement in risk stratification and primary prevention of ischemic stroke.

Author affiliations

1Department of Neurology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
2Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
3Department of Biostatistics, School of Public Health, Shandong University, Jinan, Shandong, China
4Department of Clinical Epidemiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
5Department of Radiology, Shandong Medical Imaging Research Institute, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China

Acknowledgements We would like to thank the study participants for their contribution to the project.

Contributors QS, YD, and FX conceived the study, participated in its design and coordination, and helped in the drafting of the manuscript. QW, XW, XJ, and FX performed the statistical analyses. QW, XW, ShS, ML, YZ, SS, GW, and QS enrolled the patients and performed the ultrasonography and MRI scan. QW, XW, XM, and QS contributed to the discussion and were involved in drafting and revising the manuscript. All authors read and approved the final manuscript.

Funding This study was supported by the Jinan Science and Technology Bureau (201704101), Key Technology Research and Development Project of Shandong (2014GSF118106, 2015GSF201062), Natural Science Foundation of Shandong Province (ZR2017MH094), the National Natural Science Foundation of China (817110128, 81771128), and the Ministry of Sciences and Technology of the People’s Republic of China (2017YFC13104 and 2017YFC0907003), the International Science and Technology Cooperation Programme (2014DFA32830).

Competing interests None declared.

Patient consent for publication Not required.
Cardiovascular and metabolic risk

Ethics approval This study was approved by the ethical standards committee on human experimentation of Shandong Provincial Hospital, Cheeluoh College of Medicine, Shandong University and conducted in accordance with the principles for medical research involving human participants expressed in the Helsinki Declaration. All the participants provided written informed consent for study participation.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Qinjian Sun http://orcid.org/0000-0002-9323-9154

REFERENCES

1. Gorelick PB, Wong KS, Bae H-J, et al. Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. Stroke 2008;39:2396–9.

2. Planas-Baltíve A, Crespo AM, Aguilar LM, et al. The Barcelona-Asymptomatic intracranial atherosclerosis study: subclinical intracranial atherosclerosis as predictor of long-term vascular events. Atherosclerosis 2019;282:132–6.

3. Santos IS, Alencar AP, Rundeck T, et al. Low impact of traditional risk factors on carotid intima-media thickness: the ELSA-Brasil cohort. Atherosclerosis Thromb Vasc Biol 2015;35:2054–9.

4. Wang J, Wu J, Zhang S, et al. Elevated fasting glucose as a potential predictor for asymptomatic cerebral artery stenosis: a cross-sectional study in Chinese adults. Atherosclerosis 2014;237:661–5.

5. Wang Y-L, Leng X-Y, Dong Y, et al. Fasting glucose and Hba1c levels as risk factors for the presence of intracranial atherosclerotic stenosis. Ann Trans Med 2019;7:804.

6. Bjornstad P, Eckett RH. Pathogenesis of lipid disorders in insulin resistance, a brief review. Curr Diab Rep 2018;18:127.

7. Stöhr R, Federici M. Insulin resistance and atherosclerosis: convergence between metabolic pathways and inflammatory nodes. Biochem J 2013;454:1–11.

8. Kim J-a, Montagnani M, Koh KK, et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006;113:1888–904.

9. López-Cancio E, Galán A, Dorado L, et al. Biological signatures of asymptomatic extra- and intracranial atherosclerosis: the Barcelona-Asia (asymptomatic intracranial atherosclerosis) study. Stroke 2012;43:2712–5.

10. Bos D, van der Rijk MJM, Geeraedts TEA, et al. Intracranial carotid artery atherosclerosis: prevalence and risk factors in the general population. Stroke 2012;43:1878–84.

11. Yamazoe M, Hisamatsu T, Miura K, et al. Relationship of insulin resistance to prevalence and progression of coronary artery calcification beyond metabolic syndrome components: Shiga epidemiological study of subclinical atherosclerosis. Atherosclerosis Thromb Vasc Biol 2016;36:1703–8.

12. Kozakova M, Natali A, Dekker J, et al. Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. Atheroscler Thromb Vasc Biol 2013;33:1409–17.

13. Albora E, Targer G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57–63.

14. Sun G, Wang C, Wang X, et al. Prevalence and cardiovascular risk factors of asymptomatic intracranial arterial stenosis: the Kongcun town study in Shandong, China. Eur J Neurol 2020;27:729–35.

15. Wang X, Zhao Y, Ji X, et al. Kongcun town asymptomatic intracranial artery stenosis study in Shandong, China: cohort profile. BMJ Open 2020;10:e004604.

16. Feldmann E, Wilterdink JL, Kosinski A, et al. The stroke outcomes and neuroimaging of intracranial atherosclerosis (SONIA) trial. Neurology 2007;68:2099–106.

17. Samuels OB, Joseph GJ, Lynn MJ, et al. A standardized method for measuring intracranial arterial stenosis. AJNR Am J Neuroradiol 2000;21:643–6.

18. Zhu B, Liu H, Pan Y, et al. Elevated neutrophil and presence of intracranial artery stenosis increase the risk of recurrent stroke. Stroke 2018;49:2294–300.

19. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9.

20. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International diabetes Federation Task force on epidemiology and prevention; National heart, lung, and blood Institute; American heart association; world heart Federation; international atherosclerosis Society; and international association for the study of obesity. Circulation 2009;120:1640–5.

21. Ormazabal V, Nair S, Efekoy O, et al. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 2018;17:122.

22. Varga B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia 2015;58:886–99.

23. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 2011;14:575–85.

24. Sung K-C, Choi J-H, Gwon H-C, et al. Relationship between insulin resistance and coronary artery calcium in young men and women. PLoS One 2013;8:e53316.

25. Ali SS, Xiong C, Lucero J, et al. Gender differences in free radical homeostasis during aging: shorter-lived female C57BL6 mice have increased oxidative stress. Aging Cell 2006;5:565–74.

26. Borrás C, Sastre J, García-Sala D, et al. Mitochondria from females exhibit higher antioxidant gene expression and lower oxidative damage than males. Free Radic Biol Med 2003;34:546–52.

27. Zhang M, Liu S, Yang L, et al. Prevalence of Smoking and Knowledge About the Hazards of Smoking Among 170 000 Chinese Adults, 2013-2014. Nicotine Tob Res 2019;21:1644–51.

28. Liu S, Zhang M, Yang L, et al. Prevalence and patterns of tobacco smoking among Chinese adult men and women: findings of the 2010 national smoking survey. J Epidemiol Community Health 2017;71:154–61.

29. Millwood IY, Li L, Smith M, et al. Alcohol consumption in 0.5 million people from 10 diverse regions of China: prevalence, patterns and socio-demographic and health-related correlates. Int J Epidemiol 2013;42:816–27.